We are live on ! Find out more
DP

Diadema Partners Portfolio holdings

AUM $588M
1-Year Est. Return 182.75%
This Fund
S&P 500
This Quarter Est. Return
+47.67%
1 Year Est. Return
+182.75%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$391M
AUM Growth
+$62.8M
Cap. Flow
+$27.8M
Cap. Flow %
7.12%
Top 10 Hldgs %
31.01%
Holding
170
New
75
Increased
15
Reduced
22
Closed
40

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$13.9M
2
BMY icon
Bristol-Myers Squibb
BMY
+$6.07M
3
INDV icon
Indivior Pharmaceuticals
INDV
+$5.32M
4
ASND icon
Ascendis Pharma A/S
ASND
+$5.14M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$4.07M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$14.5M
2
LLY icon
Eli Lilly
LLY
+$11M
3
TGTX icon
TG Therapeutics
TGTX
+$10.2M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$9.76M
5
SLNO
Soleno Therapeutics
SLNO
+$7.92M

Sector Composition

Rank Sector Weight
1 Healthcare 36.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBIX icon
26
Neurocrine Biosciences
NBIX
$16.8B
$5.3M 1.36%
37,754
-56,288
-60% -$7.63M
VKTX icon
27
Viking Therapeutics
VKTX
$3.7B
$5.09M 1.3%
193,689
-3,779
-2% -$113K
APGE icon
28
CALL
Apogee Therapeutics
APGE
$10.1B
$5.06M 1.29%
127,400
-28,900
-18% -$1.1M
ALNY icon
29
Alnylam Pharmaceuticals
ALNY
$27.5B
$4.56M 1.17%
+10,000
New +$4.07M
ROIV icon
30
PUT
Roivant Sciences
ROIV
$24.5B
$4.54M 1.16%
+300,000
New +$3.71M
IMCR icon
31
Immunocore
IMCR
$1.72B
$4.52M 1.16%
124,384
+20,000
+19% +$679K
RARE icon
32
CALL
Ultragenyx Pharmaceutical
RARE
$2.45B
$4.51M 1.15%
150,000
-67,000
-31% -$2.01M
NKTR icon
33
Nektar Therapeutics
NKTR
$2.39B
$4.27M 1.09%
+75,000
New +$2.48M
HRMY icon
34
CALL
Harmony Biosciences
HRMY
$2.04B
$4.13M 1.06%
+150,000
New +$5.17M
UPB
35
CALL
Upstream Bio Inc
UPB
$343M
$3.76M 0.96%
+200,000
New +$3.11M
SRRK icon
36
CALL
Scholar Rock
SRRK
$5.67B
$3.72M 0.95%
+100,000
New +$3.5M
RARE icon
37
PUT
Ultragenyx Pharmaceutical
RARE
$2.45B
$3.71M 0.95%
123,300
– –
ABVX
38
Abivax
ABVX
$10.9B
$3.51M 0.9%
+41,620
New +$2.55M
RXRX icon
39
CALL
Recursion Pharmaceuticals
RXRX
$1.59B
$3.41M 0.87%
698,400
– –
PTGX icon
40
Protagonist Therapeutics
PTGX
$8.79B
$3.4M 0.87%
51,185
-25,000
-33% -$1.42M
SLNO
41
CALL
DELISTED
Soleno Therapeutics
SLNO
$3.38M 0.86%
+50,000
New +$3.71M
ZYME icon
42
CALL
Zymeworks
ZYME
$1.61B
$3.36M 0.86%
196,500
+17,200
+10% +$246K
MREO
43
CALL
Mereo BioPharma
MREO
$54.7M
$3.13M 0.8%
1,520,200
+202,600
+15% +$374K
JAZZ icon
44
Jazz Pharmaceuticals
JAZZ
$15.9B
$3.05M 0.78%
23,140
-81,333
-78% -$9.76M
ANIP icon
45
ANI Pharmaceuticals
ANIP
$1.8B
$2.88M 0.74%
+31,400
New +$2.56M
COGT icon
46
CALL
Cogent Biosciences
COGT
$6.65B
$2.87M 0.73%
200,000
+193,100
+2,799% +$2.29M
ARCT icon
47
PUT
Arcturus Therapeutics
ARCT
$164M
$2.78M 0.71%
+150,900
New +$2.42M
RVMD icon
48
Revolution Medicines
RVMD
$39.9B
$2.76M 0.71%
59,079
-20,000
-25% -$783K
MRNA icon
49
CALL
Moderna
MRNA
$21.8B
$2.64M 0.67%
102,100
– –
SCPH
50
CALL
DELISTED
scPharmaceuticals
SCPH
$2.62M 0.67%
462,000
-24,500
-5% -$125K
1
2
3 4 5

Similar funds

MC
Martin & Co Knoxville, Tennessee $587M AUM 16.39% 1-Year Est. Return
PFG
Premier Financial Group Eureka, California $587M AUM 21.88% 1-Year Est. Return
FMI
Frec Markets Inc San Francisco, California $587M AUM
EGWAG
Elwood & Goetz Wealth Advisory Group Athens, Georgia $589M AUM 19.26% 1-Year Est. Return
PFG
PAX Financial Group San Antonio, Texas $586M AUM 15.84% 1-Year Est. Return
GIM
Garden Investment Management Greenwich, Connecticut $586M AUM 15.35% 1-Year Est. Return
FL
Fourthstone LLC St Louis, Missouri $590M AUM 29.58% 1-Year Est. Return
BA
Bellwether Advisors Lincoln, Nebraska $590M AUM 35.66% 1-Year Est. Return

Diadema Partners's Q3 2025 Portfolio in Review

As of Q3 2025, Diadema Partners held 170 positions worth $391M, up 19% from $328M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Diadema Partners deployed $27.8M of net new capital in Q3 2025, opening 75 new positions and adding to 15 existing holdings. Its largest new stake was Bristol-Myers Squibb: 130,000 shares worth $5.86M.

By sector, the portfolio is most concentrated in Healthcare at 37% of assets, down from 49% a quarter earlier.

On the sell side, the largest reduction was TG Therapeutics, an estimated $10.2M trimmed.

  • Diadema Partners's largest Q3 2025 buy was Bristol-Myers Squibb: 130,000 shares worth $5.86M.
  • Diadema Partners added most to Regeneron Pharmaceuticals in Q3 2025, an estimated $13.9M increase.
  • Diadema Partners's biggest Q3 2025 reduction was TG Therapeutics, cutting an estimated $10.2M.
  • Diadema Partners fully exited Amgen in Q3 2025, selling an estimated $14.5M.
  • Diadema Partners's ten largest holdings make up 31% of its $391M portfolio in Q3 2025.
  • Diadema Partners opened 75 new positions and closed 40 in Q3 2025.
  • Diadema Partners's portfolio value rose 19% quarter-over-quarter to $391M.

Based on Diadema Partners's 13F filing for Q3 2025, filed 14 Nov 2025.